Decisions Resources Group, a healthcare research and data company, suggests that the launch of new medicines could be a long-term management alternative to uterine fibroids surgeries over the next 10 years. Novel selective progesterone receptor modulators (SPRMs) like Allergan/Gedeon Richter’s ulipristal, Bayer’s vilaprisan and Repros’s Proellex – and gonadotropin-releasing hormone (Gn-RH) antagonists like AbbVie’s elagolix, […]